Compare CSWC & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSWC | NVAX |
|---|---|---|
| Founded | 1961 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Textiles | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | 1994 | 1996 |
| Metric | CSWC | NVAX |
|---|---|---|
| Price | $23.03 | $10.66 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 5 | 9 |
| Target Price | ★ $23.50 | $11.33 |
| AVG Volume (30 Days) | 614.7K | ★ 5.0M |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | ★ 10.89% | N/A |
| EPS Growth | 29.25 | ★ 309.76 |
| EPS | ★ 0.39 | N/A |
| Revenue | $10,835,000.00 | ★ $1,123,479,000.00 |
| Revenue This Year | $17.45 | N/A |
| Revenue Next Year | $10.26 | N/A |
| P/E Ratio | $59.08 | ★ N/A |
| Revenue Growth | 16.08 | ★ 64.69 |
| 52 Week Low | $19.37 | $6.20 |
| 52 Week High | $25.75 | $11.85 |
| Indicator | CSWC | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 31.78 | 64.76 |
| Support Level | $22.82 | $8.42 |
| Resistance Level | $23.86 | $10.85 |
| Average True Range (ATR) | 0.38 | 0.53 |
| MACD | -0.13 | 0.05 |
| Stochastic Oscillator | 12.27 | 76.77 |
Capital Southwest Corp is a U.S.-based investment company that specializes in providing customized financing to middle market companies across various industries. The company's investment objective is to produce attractive risk-adjusted returns by generating current income from debt investments and capital appreciation from equity and equity related investments. It focuses on providing flexible financing solutions through partnerships with business owners, management teams, and financial sponsors. The company's portfolio may include senior debt, second lien, and subordinated debt, preferred stocks, common stocks, and warrants. The primary source of revenue comprises interest income and dividend income from investments made as well as management fees.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.